ew therapeutic regimen for patients with hormone-resistant prostate cancer: Phase II-III clinical trial using the anti-inflammatory with the highest anti-tumor effect in pre-clinical trials (meclo/mefenamate) combined with standard treatment (Docetaxel) - MEFEPROST

Medical School of the University of Colima, Mexico0 个研究点目标入组 40 人开始时间: 2017年8月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Treatment

•1. Clinical and histological diagnosis of castration-resistant prostate cancer.
•2. That the treating oncologist considers that the administration of Docetaxel is the feasible and appropriate treatment for the patient (for control group 1 and experimental group 1).
•3. Functional status ECOG 0 to 2.
•4 Patients with no history of hepatic impairment or renal impairment (creatinine clearance should be greater than 60 milliliters / minute).
•5. Sign written informed consent of the patient.

•1. ECOG 3 or greater
•2. Diagnosis of second primary cancer.
•3. Patients with uncontrolled arterial hypertension
•4. Creatinine clearance less than 60 milliliters per minute
•5. Leukocytes less than 3000 cells / microliter or platelet count less than 100,000 cells / microliter 6. Leukocytes greater than 10,000 cells / microliter or showing data Of systemic infection
•7. Blood hemoglobin less than 9gr / deciliter 8. Alcoholism and / or drug addiction
•9. Gastrointestinal ulcer
•10. Inflammatory bowel disease
•11. Diagnosis of ischemic heart disease
•12. Other pathologies at the discretion of the investigator.

发起方

Medical School of the University of Colima, Mexico